Best Medical & Nursing Services Stocks 2021
$ 4.13 M to $ 12.66 B
$0.02 to $586.17
-24% to 171.8%
-1460.43 to 472.49
DaVita Inc

DaVita Inc. is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of December 31, 2020, DaVita served 204,200 patients at 2,816 outpatient dialysis centers in the United States. The company also operated 321 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere.
DaVita Inc or DVA is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 12.66 B. Javier Rodriguez is the CEO of the company. Total employees of DaVita Inc are 2,020. The P/E Ratio of DaVita Inc is 16.07 and year till date stock price change percent is 44.76%.
Chemed Corp.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services.
Chemed Corp. or CHE is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 8.82 B. Kevin McNamara is the CEO of the company. Total employees of Chemed Corp. are 15,544. The P/E Ratio of Chemed Corp. is 29.74 and year till date stock price change percent is 0.48%.
Ensign Group Inc

The Ensign Group independent operating subsidiaries provide a broad spectrum of skilled nursing and assisted living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 231 healthcare facilities, in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin.
Ensign Group Inc or ENSG is traded on NASDAQ. The total market value of the company is $ 8.64 B. Barry Port is the CEO of the company. Total employees of Ensign Group Inc are 24,400. The P/E Ratio of Ensign Group Inc is 38.71 and year till date stock price change percent is 34.87%.
Acadia Healthcare Company Inc

Acadia is a leading provider of behavioral healthcare services across the United States. Acadia operates a network of 227 behavioral healthcare facilities with approximately 9,900 beds in 40 states and Puerto Rico. With more than 20,000 employees serving approximately 70,000 patients daily, Acadia is the largest stand-alone behavioral health company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Acadia Healthcare Company Inc or ACHC is traded on NASDAQ. The total market value of the company is $ 7.61 B. Debra Osteen is the CEO of the company. Total employees of Acadia Healthcare Company Inc are 35,400. The P/E Ratio of Acadia Healthcare Company Inc is -1460.43 and year till date stock price change percent is 5.31%.
LHC Group Inc

LHC Group, Inc. is a national provider of in-home healthcare services and innovations for communities around the nation, offering quality, value-based healthcare to patients primarily within the comfort and privacy of their home or place of residence. The company's approximately 30,000 employees deliver home health, hospice, home and community based services, and facility-based care in 35 states and the District of Columbia - reaching 60 percent of the U.S. population aged 65 and older. As the preferred joint venture partner for almost 400 leading U.S. hospitals and health systems, LHC Group works in cooperation with providers to customize each partnership and reach more patients and families with an effective and efficient model of care.
LHC Group Inc or LHCG is traded on NASDAQ. The total market value of the company is $ 5.29 B. Keith Myers is the CEO of the company. Total employees of LHC Group Inc are 21,150. The P/E Ratio of LHC Group Inc is 82.83 and year till date stock price change percent is 0.47%.
Radnet Inc

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 334 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey, New York and Arizona. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 8,600 employees.
Radnet Inc or RDNT is traded on NASDAQ. The total market value of the company is $ 4.90 B. Howard Berger is the CEO of the company. Total employees of Radnet Inc are 6,420. The P/E Ratio of Radnet Inc is 472.49 and year till date stock price change percent is 88.52%.
Amedisys Inc.

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for its patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,900 hospitals and 78,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With ~21,000 employees, in 514 care centers in 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 418,000 patients in need every year.
Amedisys Inc. or AMED is traded on NASDAQ. The total market value of the company is $ 3.21 B. Paul Kusserow is the CEO of the company. Total employees of Amedisys Inc. are 2,020. The P/E Ratio of Amedisys Inc. is 35 and year till date stock price change percent is 3.1%.
Guardant Health Inc

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Guardant Health Inc or GH is traded on NASDAQ. The total market value of the company is $ 3.15 B. is the CEO of the company. Total employees of Guardant Health Inc are 864. The P/E Ratio of Guardant Health Inc is -6.27 and year till date stock price change percent is -5.49%.
Addus HomeCare Corporation

Addus HomeCare is a provider of home care services that primarily include personal care services that assist with activities of daily living, as well as hospice and home health services. Addus HomeCare's consumers are primarily persons who, without these services, are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Addus HomeCare's payor clients include federal, state and local governmental agencies, managed care organizations, commercial insurers and private individuals. Addus HomeCare currently provides home care services to approximately 44,000 consumers through 212 locations across 22 states.
Addus HomeCare Corporation or ADUS is traded on NASDAQ. The total market value of the company is $ 2.41 B. R. Dirk Allison is the CEO of the company. Total employees of Addus HomeCare Corporation are 20,583. The P/E Ratio of Addus HomeCare Corporation is 31.59 and year till date stock price change percent is 42.65%.
Neogenomics Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Neogenomics Inc. or NEO is traded on NASDAQ. The total market value of the company is $ 2.12 B. is the CEO of the company. Total employees of Neogenomics Inc. are 1,700. The P/E Ratio of Neogenomics Inc. is -26.51 and year till date stock price change percent is 2.09%.
Tivity Health Inc

Tivity Health® Inc. is a leading provider of healthy life-changing solutions, including SilverSneakers®, Nutrisystem®, Prime® Fitness, Wisely Well™, South Beach Diet®, and WholeHealth Living®. We are actively addressing the social determinants of health, defined as the conditions in which we work, live and play. From improving health outcomes to reversing the narrative on inactivity, food insecurity, social isolation and loneliness, we are making a difference and are transforming the way we do health.
Tivity Health Inc or TVTY is traded on NASDAQ. The total market value of the company is $ 1.62 B. Robert Greczyn is the CEO of the company. Total employees of Tivity Health Inc are 350. The P/E Ratio of Tivity Health Inc is 19.01 and year till date stock price change percent is 0.06%.
U.S. Physical Therapy, Inc.

Founded in 1990, U.S. Physical Therapy, Inc. operates 548 outpatient physical therapy clinics in 39 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 38 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
U.S. Physical Therapy, Inc. or USPH is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 1.29 B. Christopher Reading is the CEO of the company. Total employees of U.S. Physical Therapy, Inc. are 3,590. The P/E Ratio of U.S. Physical Therapy, Inc. is 80.75 and year till date stock price change percent is -6.71%.
Pennant Group Inc

The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through 80 home health and hospice agencies and 54 senior living communities located throughout Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated 'company' and 'its' assets and activities, as well as the use of the terms 'we,' 'us,' 'its' and similar verbiage, are not meant to imply that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the home health and hospice businesses, senior living communities or the Service Center are operated by the same entity.
Pennant Group Inc or PNTG is traded on NASDAQ. The total market value of the company is $ 1.03 B. is the CEO of the company. Total employees of Pennant Group Inc are 5,223. The P/E Ratio of Pennant Group Inc is 53.89 and year till date stock price change percent is 141.49%.
MEDNAX Inc

Mednax, Inc. is a national medical group comprised of the nation's leading providers of physician services. Physicians and advanced practitioners practicing as part of Mednax are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telehealth programs to enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional entities, Mednax provides services through a network of more than 2,300 physicians in 39 states and Puerto Rico.
MEDNAX Inc or MD is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 932.50 M. is the CEO of the company. Total employees of MEDNAX Inc are 5,600. The P/E Ratio of MEDNAX Inc is -3.56 and year till date stock price change percent is 17.06%.
Castle Biosciences Inc

Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq).Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.
Castle Biosciences Inc or CSTL is traded on NASDAQ. The total market value of the company is $ 819.11 M. is the CEO of the company. Total employees of Castle Biosciences Inc are 200. The P/E Ratio of Castle Biosciences Inc is -263.5 and year till date stock price change percent is 37.64%.
Hanger Inc

About Hanger, Inc.- Hanger, Inc. delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger's Patient Care segment is the largest owner and operator of O&P patient care clinics withapproximately 800locationsnationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. With nearly 160 years of clinical excellence and innovation, Hanger's vision is to lead the orthotic and prosthetic markets by providing superior patient care, outcomes, services and value.
Hanger Inc or HNGR is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 732.39 M. Vinit Asar is the CEO of the company. Total employees of Hanger Inc are 4,700. The P/E Ratio of Hanger Inc is 19.76 and year till date stock price change percent is 3.25%.
Fulgent Genetics Inc

Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing ('NGS') with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company's advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus ('COVID-19'), including NGS and reverse transcription polymerase chain reaction ('RT-PCR') - based tests. The Company has received Emergency Use Authorization ('EUA') from the U.S. Food and Drug Administration ('FDA') for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Company's business is its ability to provide expansive options and flexibility for all clients' unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.
Fulgent Genetics Inc or FLGT is traded on NASDAQ. The total market value of the company is $ 683.49 M. Ming Hsieh is the CEO of the company. Total employees of Fulgent Genetics Inc are 429. The P/E Ratio of Fulgent Genetics Inc is -4.13 and year till date stock price change percent is -22.45%.
Ares Acquisition Corporation

Ares Acquisition Corporation or AAC is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 492.07 M. is the CEO of the company. Total employees of Ares Acquisition Corporation are 3. The P/E Ratio of Ares Acquisition Corporation - Class A is and year till date stock price change percent is 7.34%.
Catasys, Inc.

Catasys, Inc. provides data analytics based specialized behavioral health management and integrated treatment services to health plans. It offers services through its platform OnTrak solution which is designed to improve member health and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
Catasys, Inc. or CATS is traded on NASDAQ. The total market value of the company is $ 441.67 M. Terren S. Peizer is the CEO of the company. Total employees of Catasys, Inc. are 395. The P/E Ratio of Catasys, Inc. is -14.17 and year till date stock price change percent is 0%.
American Renal Associates Holdings Inc.

American Renal Associates Holdings Inc. or ARA is traded on NEW YORK STOCK EXCHANGE, INC.. The total market value of the company is $ 397.25 M. Joseph Carlucci is the CEO of the company. Total employees of American Renal Associates Holdings Inc. are . The P/E Ratio of American Renal Associates Holdings Inc. is and year till date stock price change percent is 0.44%.
Global Cord Blood Corp

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.
Global Cord Blood Corp or CO is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 363.15 M. is the CEO of the company. Total employees of Global Cord Blood Corp are 1,260. The P/E Ratio of Global Cord Blood Corp is and year till date stock price change percent is 0%.
BioPlus Acquisition Corp

BioPlus Acquisition Corp or BIOS is traded on NASDAQ. The total market value of the company is $ 252.09 M. is the CEO of the company. Total employees of BioPlus Acquisition Corp are 2,021. The P/E Ratio of BioPlus Acquisition Corp - Class A is and year till date stock price change percent is 4.69%.
OptiNose Inc

Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S. and Norway.
OptiNose Inc or OPTN is traded on NASDAQ. The total market value of the company is $ 156.81 M. Peter Miller is the CEO of the company. Total employees of OptiNose Inc are 206. The P/E Ratio of OptiNose Inc is -3.1 and year till date stock price change percent is -19.86%.
Smiledirectclub Inc

SmileDirectClub, Inc. ('SmileDirectClub') is an oral care company and creator of the first medtech platform for teeth straightening, now also offered directly via dentist and orthodontist offices. Through its proprietary technology and vertically integrated model, SmileDirectClub is revolutionizing the oral care industry, offering consumers the ability to get clinically safe and effective treatment but without the 3x markup associated with traditional orthodontics. SmileDirectClub's mission is to democratize access to a smile each and every person loves by making it affordable and convenient for everyone, from clear aligner therapy to premium oral care products. SmileDirectClub is headquartered in Nashville, Tennessee and operates in the U.S., Canada, Australia, New Zealand, United Kingdom, Ireland, Germany, Austria, Spain, Netherlands, Hong Kong and Singapore.
Smiledirectclub Inc or SDC is traded on NASDAQ. The total market value of the company is $ 100.66 M. is the CEO of the company. Total employees of Smiledirectclub Inc are 4,000. The P/E Ratio of Smiledirectclub Inc - Class A is -3.5 and year till date stock price change percent is 126.62%.
Pro-Dex Inc. (co)

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. It has patented adoptive torque-limiting software and proprietary sealing solutions which appeal to its customers, primarily medical device distributors. Pro-Dex also sells rotary air motors to a wide range of industries. Pro-Dex's products are found in hospitals and medical engineering labs around the world.
Pro-Dex Inc. (co) or PDEX is traded on NASDAQ. The total market value of the company is $ 79.77 M. Richard Van Kirk is the CEO of the company. Total employees of Pro-Dex Inc. (co) are 119. The P/E Ratio of Pro-Dex Inc. (co) is 19.12 and year till date stock price change percent is 32.87%.